## CHALLENGES IN CANCER: ANSWERING THE DIFFICULT QUESTIONS

### ANNUAL MEETING AGENDA

**Wednesday, September 7, 2011**

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.15</td>
<td>Registration</td>
<td></td>
</tr>
<tr>
<td>8.45</td>
<td>Welcome Remarks</td>
<td>Dennis McCance, PhD, Centre for Cancer Research and Cell Biology, Queen’s University Belfast</td>
</tr>
<tr>
<td>9.00</td>
<td>Overview: Follow on from STO meeting in Boston, 2010</td>
<td>Patrick G. Johnston, MD, PhD, Dean, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast</td>
</tr>
<tr>
<td>9.30</td>
<td>SESSION 1A: PATIENT STRATIFICATION</td>
<td></td>
</tr>
<tr>
<td></td>
<td>EGFR mutation analysis: A paradigm for the Future of Therapeutic Pathology and Personalised Medicine</td>
<td>Manuel Salto-Tellez, MD, Centre for Cancer Research and Cell Biology, Queen’s University Belfast</td>
</tr>
<tr>
<td>10.00</td>
<td>Stratified Cancer Medicine: theory and practice</td>
<td>Peter Johnson, PhD, Cancer Research UK University of Southampton, UK</td>
</tr>
<tr>
<td>10.30</td>
<td>Lung cancer genomics</td>
<td>Roman Thomas, MD, Max Planck Institute for Neurological Research, Cologne, Germany</td>
</tr>
<tr>
<td>11.00</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>11.30</td>
<td>SESSION 1B: PRECLINICAL MODELS OF STRATIFICATION</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Identification of a DNA Damage Response Deficient Subtype in Breast Cancer</td>
<td>Richard Kennedy, MB, PhD, Almac Diagnostics, Northern Ireland</td>
</tr>
<tr>
<td>12.00</td>
<td>Using Synthetic Lethality Approaches to Design Novel Therapeutic Approaches to Cancer Treatment</td>
<td>Chris Lord, PhD, Breakthrough Breast Cancer, Institute of Cancer Research, London</td>
</tr>
<tr>
<td>12.30</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>1.30</td>
<td>SESSION 2: MODELS OF DISEASE - RELEVANCE</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Modeling Human Colorectal Cancer In The Mouse: Modifying Wnt driven neoplasia</td>
<td>Alan Clarke, PhD, Cardiff School of Biosciences, Wales, UK</td>
</tr>
<tr>
<td>2.00</td>
<td>Pancreatic Cancer Medicine</td>
<td>Dave Tuveson, MD, PhD, Cancer Research UK Cambridge Research Institute, Cambridge, UK</td>
</tr>
<tr>
<td>2.30</td>
<td>Investigating the impact of KRAS mutation in mouse models of intestinal cancer</td>
<td>Owen Sansom, PhD, Beatson Institute for Cancer Research, Glasgow</td>
</tr>
<tr>
<td>3.00</td>
<td>Translating NRAS and BRAF biology into therapeutics</td>
<td>Richard Marais, PhD, Cell &amp; Molecular Biology/CRUK Tumour Cell Signalling Unit, Chester Beatty Laboratories, London</td>
</tr>
<tr>
<td>3.30</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>4.00</td>
<td>2011 BOB PINEDO CANCER CARE PRIZE AWARD and KEYNOTE LECTURE</td>
<td>Introduction by Patrick G. Johnston, MD, PhD Speaker: Gabriel N. Hortobágyi, MD, University of TX MD Anderson Cancer Center</td>
</tr>
<tr>
<td>5.00</td>
<td>Poster Session</td>
<td></td>
</tr>
<tr>
<td>7.30</td>
<td>Reception &amp; Conference Dinner</td>
<td>City Hall, Belfast</td>
</tr>
</tbody>
</table>
### Thursday, September 8, 2011

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Description</th>
<th>Speaker Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.15</td>
<td>Introduction</td>
<td>Hyman Muss, MD, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC</td>
</tr>
<tr>
<td></td>
<td><strong>SESSION 3: ADAPTIVE TRIAL STRATEGIES</strong></td>
<td><strong>Chairs:</strong> Hyman Muss, MD, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC</td>
</tr>
<tr>
<td></td>
<td><strong>Andrew Hughes, MB, MRCP, PhD, Astra Zeneca, Cheshire</strong></td>
<td><strong>Sandra van Schaeybroeck, MD, PhD, Centre for Cancer Research &amp; Cell Biology,</strong> Queen’s University Belfast</td>
</tr>
<tr>
<td></td>
<td><strong>8.30 Targeting oncogenic Kras in colorectal cancer</strong></td>
<td><strong>Sabine Tejpar, MD, PhD, Digestive Oncology Unit, Centre for Human Genetics,</strong> University Hospital Gasthuisberg, Leuven, Belgium</td>
</tr>
<tr>
<td></td>
<td><strong>9.00 Understanding cancer biology for successful drug development</strong></td>
<td><strong>Johann de Bono, MD, PhD, Institute of Cancer Research,</strong> Royal Marsden Hospital, Sutton</td>
</tr>
<tr>
<td></td>
<td><strong>9.30 Recent successes in anticancer drug development</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>10.30 Break</strong></td>
<td><strong>Chairs:</strong> Sabine Tejpar, MD, PhD, Digestive Oncology Unit, Centre for Human Genetics,** University Hospital Gasthuisberg Joe O’Sullivan, MD, Centre for Cancer Research and Cell Biology, Queen’s University Belfast</td>
</tr>
<tr>
<td></td>
<td><strong>10.30 PARP inhibitors - combination and single agent clinical trials and biomarker development</strong></td>
<td><strong>Ruth Plummer, PhD, Northern Institute for Cancer Research,</strong> University of Newcastle-upon-Tyne</td>
</tr>
<tr>
<td></td>
<td><strong>11.00 Personalized Therapy for Advanced Non-small cell lung cancer: Lessons Learned from the BATTLE Trial</strong></td>
<td><strong>Roy S Herbst, MD, PhD, Yale Cancer Center, New Haven, CT</strong></td>
</tr>
<tr>
<td></td>
<td><strong>11.30 Targeting apoptotic and non-apoptotic death pathways for effective therapy of thoracic cancer</strong></td>
<td><strong>Dean Fennell, MB, PhD, Centre for Cancer Research &amp; Cell Biology,</strong> Queen’s University Belfast</td>
</tr>
<tr>
<td></td>
<td><strong>12.00 2011 McClay FOUNDATION LECTURE</strong></td>
<td><strong>Introduction by Richard Kennedy, MB, PhD (Visiting McClay Chair)</strong> University of North Carolina &amp; North Carolina Cancer Hospital</td>
</tr>
<tr>
<td></td>
<td><strong>Maximizing the Harvest: A Parable Drawn from the Phase III NCCTG N9741 Study in Patients with Metastatic Colorectal Cancer</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>1.00 Lunch</strong></td>
<td><strong>SESSION 4: ACADEMIC AND INDUSTRIAL PARTNERSHIPS IN STRATIFIED MEDICINE</strong></td>
</tr>
<tr>
<td></td>
<td><strong>1.45 Evolution of Cancer Chemotherapy</strong></td>
<td><strong>Richard Kennedy, MB, PhD, Almac Diagnostics,</strong> Northern Ireland Patrick G. Johnston, MD, PhD, Dean, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast</td>
</tr>
<tr>
<td></td>
<td><strong>2.15 Academic and Industrial partnerships in stratified medicine: competition or collaboration?</strong></td>
<td><strong>Andrew Hughes, MB, MRCP, PhD, AstraZeneca</strong></td>
</tr>
<tr>
<td></td>
<td><strong>2.45 To be confirmed</strong></td>
<td><strong>Tamas Suto, MD, PhD, sanofi-aventis</strong></td>
</tr>
<tr>
<td></td>
<td><strong>PRESENTATION OF PROFFERED PAPERS</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>3.05 Establishing a molecular taxonomy for epithelial ovarian cancer (EOC) from 363 formalin-fixed paraffin embedded (FFPE) specimens</strong></td>
<td><strong>Katherine Keating, Almac Diagnostics</strong></td>
</tr>
<tr>
<td></td>
<td><strong>3.15 DNMT1 deficiency triggers mismatch repair defects in human cells through depletion of repair protein levels in a process involving the DNA damage response</strong></td>
<td><strong>Colum Walsh, University of Ulster</strong></td>
</tr>
<tr>
<td></td>
<td><strong>3.25 Phase 3 population-based study reveals new risk-stratification biomarker panel for Barrett’s oesophagus</strong></td>
<td><strong>Damian McManus, Centre for Cancer Research &amp; Cell Biology,</strong> Belfast Health &amp; Social Care Trust</td>
</tr>
<tr>
<td></td>
<td><strong>3.35 Identification of novel BRCA1 transcriptional targets that promote the survival of BRCA1-mutated, estrogen receptor-α negative (ER-ve) breast tumours</strong></td>
<td><strong>Elizabeth Lamers, Centre for Cancer Research &amp; Cell Biology</strong></td>
</tr>
<tr>
<td></td>
<td><strong>3.45 Concluding Remarks</strong></td>
<td><strong>Bruce A. Chabner, MD, Massachusetts General Hospital Cancer Center,</strong> Harvard Medical School</td>
</tr>
<tr>
<td></td>
<td><strong>4.00-6.00 PROSTATE CANCER: Progress and Promise</strong></td>
<td><strong>Chairman and Moderator:</strong> Bruce A. Chabner, MD Participating Faculty:** Johann de Bono, MD, PhD Joe O’Sullivan, MD David Waugh, PhD**</td>
</tr>
</tbody>
</table>
Overview

This features a renowned group of faculty and speakers who will encourage collaborative dialogue about the major challenges in cancer, including usefulness of animal models, drug resistance, patient stratification, adaptive trials and how academia can interact with industry for the betterment of cancer treatment.

Learning Objectives

At the conclusion of this meeting, learners will be better able to:

- Interpret new trial data, safety, and efficacy for novel investigational therapies.
- Discuss the integration of tumor profiling, non-invasive biomarker development, and use of animal models into trial design for molecular-based drug development.
- Evaluate the potential of molecular-based drug development for improving results of treatment of common and rare tumors.

Target Audience

This meeting is designed to meet the educational needs of physicians and scientists in academic and practice settings who wish to advance their knowledge of the research into new treatments and improve competence in the care of patients with cancer.

Accreditation

Challenges in Cancer: Answering the Difficult Questions has been granted accreditation approval by the Accreditation Council of Oncology in Europe (ACOE).

The ACOE is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

Challenges in Cancer: Answering the Difficult Questions is designated for a maximum of 12 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

EACCME credits are recognized by the American Medical Association towards the Physician’s Recognition Award (PRA). To convert EACCME credit to AMA PRA category 1 credit, contact the AMA.

Challenges in Cancer: Answering the Difficult Questions has been accredited with 12 ESMO-MORA category 1 points.

In order to claim CME credit, please complete the electronic evaluation survey you receive by e-mail following the meeting and indicate the type and number of credits claimed. Certificates will be provided upon successful completion of the survey.
Financial Disclosures

It is the policy of the Society for Translational Oncology (STO) to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities through the disclosure of financial interests and other relationships.

As the accredited CME provider, STO must comply with the UEMS/EACCME requirement that all planners and speakers participating in this program disclose any potential conflicts of interest or support that might cause a bias in their presentation; this form has therefore been adopted to identify any potential conflicts of interest.

In accordance with UEMS/EACCME policy, all potential conflicts of interest relevant to this event will be declared to the audience prior to the start of the CME activity. Any conflicts of interest found will be resolved prior to the activity.

The following planners, speakers and/or staff members have indicated that they have had relevant financial relationship(s) with a commercial interest within the past 12 months or that they have nothing to disclose.

STO and CCRCB Staff involved in the development of this activity have nothing to disclose.

Faculty involved in the development of this activity have the following disclosures

Joe Bertino, MD  
Scientific Advisory Board: J&J, Celator, Ziopharm; Research funding: PTC Therapeutics  
Dr. Bertino’s presentation will discuss drugs from PTC Therapeutics.

Johann de Bono, MD, PhD  
Consultant/advisory role: Genentech, AstraZeneca, Merck, J&J, Astellas, Medivation, Dendreon; Research funding: AstraZeneca, J&J, Enzon; Property rights: Abiraterone was generated by scientists at the Institute of Cancer Research

Bruce A. Chabner, MD  
Board member: PharmaMar; Scientific Advisory Board member: Thomas McNerney and Partners, Eli Lilly, Epizyme; Consultant/advisory role: Allergan, OvaGen, Peregrine, GSK, Merrimack; Equity holdings: Covidien, Celgene, Seattle Genetics, Pharmasett, Exelixis, Gilead, Rigel, Onyx, Sagent, BMS, Human Genome Sciences, Zeltia

Alan Clarke, PhD  
Research funding: a CaSE-funded PhD studentship with AstraZeneca

Dean Fennell, MB, PhD  
To be announced

Richard Goldberg, MD  
Consultant/advisory role: Amgen, Bayer, Genentech, Genomic Health, Lilly, sanofi-aventis; Research funding: Amgen, Bayer, Genentech, sanofi-aventis, Enzon

Roy S Herbst, MD, PhD  
Scientific Advisory Boards: Biotheria, Dia Tech, N of One, SynDevRx

Gabriel Hortobágyi, MD  
Consultant/advisory role: sanofi-aventis, Novartis, Merck, Genentech, Allergan, Taivex; Research funding: Novartis

Andrew Hughes, MB, MRCP, PhD  
Employment/leadership: Vice President for Early Oncology for AstraZeneca; Scientific advisory group member and consultant: Epistem; Ownership interest: salary and stock options from AstraZeneca, consultancy payments pro-rata from Epistem; Patents: AstraZeneca

Peter Johnson, PhD  
Scientific Advisory Boards: Pfizer, Millennium Takeda, Seattle Genetics; Research funding: Janssen-Cilag; the Cancer Research UK stratified medicine programme is supported by AstraZeneca and Pfizer  
Dr. Johnson’s presentation will describe the CR UK stratified medicine programme and referring to the clinical trial supported by Janssen-Cilag.

Patrick Johnston, MD, PhD  
Employment/leadership: Almac Diagnostics; Intellectual property rights: 12 patents; Consultant/advisory role: Almac, Roche, Chugai Pharmaceuticals, sanofi-aventis; Honorary: AstraZeneca, Chugai Pharmaceuticals, Pfizer, sanofi-aventis, Roche; Research funding: AstraZeneca, Amgen; Ownership interest: Almac, Fusion Antibodies

Richard Kennedy, MB, PhD  
Employment/leadership: Almac; Research funding: academic research group receives funding from Almac Group; Property rights/patents: patent on a DNA microarray platform-based test for colon cancer. Dr. Kennedy’s presentation will discuss the DNA repair test to be developed as a product by Almac Diagnostics.

Chris Lord, PhD  
Research funding: GlaxoSmithKline, AstraZeneca; Property rights/patents: A number of patents pertaining to synthetic liability Dr. Lord’s presentation will discuss synthetic liability and PARP inhibitors

Richard Marais, PhD  
Property rights/patents: Members of the Institute of Cancer Research who have worked on programmes that are commercialized may be eligible for payments through the “Rewards to Inventors” scheme.

Dennis McCance, PhD  
Nothing to disclose

Joe O’Sullivan, MD  
To be announced

Ruth Plummer, PhD  
Research funding: AstraZeneca, Pfizer, Abbott, Cephalon, Biologics, Eisai  
Dr. Plummer’s presentation will discuss published clinical data on PARP inhibitors, and the funding disclosed supported clinical trials with these agents from a range of companies.

Manuel Salto-Téllez, MD  
Consultant/advisor: Almac, Key Opinion Leaders group of Ventana-Roche, ad-hoc advisor for AstraZeneca; Honoraria: for speaking on EGFR testing, from AstraZeneca and Roche

Owen Sansom, PhD  
Research funding: Pfizer, Novartis

Sandra van Schaeybroeck, MD, PhD  
Nothing to disclose

Tamas Suto, MD, PhD  
Employment: sanofi-aventis

Sabine Tejpar, MD, PhD  
To be announced

Roman Thomas, MD  
Consultant: J&J, Atlas Biolabs; Research funding: AstraZeneca, EOS; Advisor: AstraZeneca, Atlas Biolabs, Boehringer Ingelheim, Lilly, Merck, Roche; Property rights/patents: pending patent applications in genetically tailored cancer therapy

Dave Tuveson, MD, PhD  
Research funding: Merck

David Waugh, PhD  
Scientific Advisory Board: Almac Discovery; Advisor: Almac Group of Companies
2011 Bob Pinedo Cancer Care Prize Awardee

Gabriel N. Hortobágyi, MD, FACP
Nellie B. Connally Chair, Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

The Society for Translational Oncology is honored to award the 2011 Bob Pinedo Cancer Care Prize to Dr Gabriel Hortobágyi for his life-long dedication to cancer patients and his pioneering progress in bringing new hope to breast cancer patients. Dr Hortobágyi is widely recognized for developing combined modality therapy for previously inoperable breast tumors, improving multidisciplinary treatment for patients with all stages of the disease and conducting clinical trials to develop treatment regimens that have become standard practices for managing breast cancer. A past president of ASCO, he is on the Board of Directors of the Conquer Cancer Foundation and has previously held leadership positions with Susan G. Komen for the Cure and the International Association of Breast Cancer Research. He has been recognized for his groundbreaking research efforts with many awards, including honorary doctorates from 3 leading universities in Italy, Mexico and Argentina. He has published over 1,000 articles in the scientific literature, edited 13 books, contributed more than 140 chapters to textbooks and serves as an editor to over 23 publications. As a Senior Editor for The Oncologist and medical advisory committee member for the Society for Translational Oncology, Dr Hortobágyi advocates for ways to speed the discovery and translation of important new treatments in the field of cancer medicine to the practice of global oncology.

In honor of this award, Dr Hortobágyi will give the keynote lecture at the 2011 joint scientific meeting of STO and the Centre for Cancer Research and Cell Biology, Queen’s University Belfast, September 7-8, 2011 at the Waterfront Hall in Belfast, Northern Ireland.

About the Prize

The prize honors Professor H.M. (Bob) Pinedo, founder of the VU University Medical Center (VUmc) Cancer Center Amsterdam (CCA) who weds world-class cancer research with a devotion to his patients and their families. First presented by Medical Knowledge Institute in 2006, the Bob Pinedo Cancer Care Prize has been awarded to five distinguished physician-scientists:

- **Bruce Chabner, MD** – Massachusetts General Hospital Cancer Center
- **Joseph Bertino, MD** – The Cancer Institute of New Jersey
- **Bob Löwenberg, MD** – Erasmus University Medical Centre
- **Richard O’Reilly, MD** – Memorial Sloan-Kettering Cancer Center
- **José Baselga, MD, PhD** – Massachusetts General Hospital Cancer Center

Call for Nominations

Nominations for the 2012 Pinedo Prize should be sent to Professor Patrick Johnston, Chairman, Nominating Committee: Pinedo.Prize@STO-online.org no later than February 1, 2012. All nominees will be evaluated by an international nominating committee.

If you have questions about STO or the Bob Pinedo Cancer Care Prize, address them to: admin@sto-online.org.
McClay Foundation Lecture

Richard M Goldberg, MD
Richard M. Goldberg Distinguished Professor of Gastrointestinal Oncology
Division Chief, Hematology and Oncology
Physician-in-Chief, North Carolina Cancer Hospital
Associate Director for Clinical Research, Lineberger Comprehensive Cancer Center
University of North-Carolina at Chapel Hill
Chapel Hill, NC

The McClay Foundation lecture was initiated to honour the contributions of Sir Allen McClay to medical research, Queen’s University and the wider community.

Sir Allen was a true pioneer and great visionary.

He founded his first company, Galen, in 1968 which subsequently became Galen Holdings plc in 1997 and was Northern Ireland’s first £ billion company. Sir Allen retired from Galen in 2001 and, despite being in his 70th year, was not one to rest on his laurels and founded Almac.

Realising his vision, Almac has grown into a truly global organisation employing over 3,000 people and has added genomics and discovery to its areas of expertise. Its new $120 million North American Headquarters opened in May 2011 but whilst Sir Allen was the driving force behind it regrettably he did not see its completion.

Allen was not a man for pomp or ceremony, however, through the McClay Foundation his genuine inspirational philanthropic passion continues to this day.

The McClay Foundation is privileged to have Dr. Richard M Goldberg present the McClay Foundation lecture on September 8, 2011.

Dr. Goldberg completed his undergraduate degree at Harvard University and attended medical school at SUNY Upstate Medical University where he was elected to the honor medical society Alpha Omega Alpha. He took postgraduate training at Emory University in internal medicine and Georgetown University in medical oncology. He was a consultant and Professor of Oncology at the Mayo Clinic, Rochester and Vice Chair of the Departments of Medicine at the Geisinger Medical Center prior to moving to the University of North Carolina at Chapel Hill in 2003.

Dr Goldberg is an active member and leader of the American Society of Clinical Oncology. He has been active in a number of capacities including serving on the annual meeting Program Committees in 1991-92 and 2000-2002, 2006-2011. He was a member of the Education (1997-2000), Publications Committees (2003-6) and Ethics Committee (2007-2010). Dr Goldberg was on the editorial board (2001-2003) and remains an active reviewer for the Journal of Clinical Oncology. He is Associate Editor of the Cancer.Net Gastrointestinal Cancer section website (2004-). He is an editor of the GI Cancer section for UpToDate, on the editorial boards of The Oncologist, Clinical Colorectal Cancer, Gastrointestinal Cancer Research, and the Mayo Clinic Proceedings. In 2006 he was elected president of the International Society of Gastrointestinal Oncology. In 2009 he was elected co-chairman of the Society for Translational Oncology (STO).

His research interests include clinical and translational research in gastrointestinal cancers, particularly colorectal cancer, and the development and integration of novel treatments into the clinic. He has led and remains active in the leadership of Phase I, II, and III clinical trials testing new chemotherapy programs in patients with advanced malignancies and gastrointestinal cancers. He has collaborated in a number of studies in the genetics of inherited colorectal cancer syndromes, the interactions between genetic parameters and chemotherapy activity and toxicity, and the applications of pharmacogenetics to individualize cancer chemotherapy programs.

Dr Goldberg has been active with the American Cancer Society, the American Association of Cancer Research, the American Joint Commission on Cancer, the International Society of Gastrointestinal Cancer and other groups. He lectures frequently on topics related to GI cancer in the U.S. and internationally. Dr Goldberg has published more than 400 manuscripts and book chapters.

In October 2011 Dr Goldberg will move to Ohio State University to become Professor of Medicine, Physician-in-Chief of the James Cancer Hospital, and Associate Director of the James Cancer Center.
LEARNING OBJECTIVES – DAY 1

SESSION 1A: PATIENT STRATIFICATION

• Describe the future of molecular diagnostics, using *EGFR* mutation analysis testing as a paradigm.

• Describe the project to develop a comprehensive database of mutations and other genetic changes in tumors and explain how it will inform treatment decisions for specific sub-groups of patients.

• Describe the international network for cancer genome analyses and the platform developed for functional cell biology analysis of novel mutations discovered.

SESSION 1B: PRECLINICAL MODELS OF STRATIFICATION

• Describe the DNA damage response deficient breast cancer subtype and explain its association with sensitivity to DNA-damaging chemotherapy in estrogen receptor-positive and -negative breast cancer.

• Describe how the synthetic lethality approach can be exploited, how novel targets can be identified, and how tumor types as diverse as colorectal, breast, prostate, and endometrial cancer could be treated using this approach.

SESSION 2: MODELS OF DISEASE – RELEVANCE

• Identify genes that have been shown to influence Wnt signaling and describe their impact on Wnt-driven neoplasia

• Describe the effect of the compressed vasculature of PDA tumors on the effective delivery of chemotherapeutics and how research into the vascularization of xenograft tumors may be relevant.

• Describe the impact of additional mutation of KRAS G12D and G12V following deletion of the key intestinal tumor suppressor APC.

• Describe the proposed mechanism by which anti-BRAF agents influence skin carcinogenesis.

2011 BOB PINEDO CANCER CARE PRIZE AWARD

• Describe how advances in understanding of biomarkers that predict response or resistance to specific agents will lead to individualized cancer therapy and the design of optimal combinations based on the patient’s own tumor characteristics.
LEARNING OBJECTIVES – DAY 2

SESSION 3: ADAPTIVE TRIAL STRATEGIES

• Describe the novel treatment strategy for KrasMT CRC tumors represented by the targeting of JAK1/2-STAT3 pathway in conjunction with existing chemotherapies or MEK1/2 inhibition.

• Describe the problem of knowledge gaps in the development of oncology drugs and discuss approaches for gaining and using knowledge for drug development.

• Discuss a model of drug development based on integrated cancer research and biomarker-driven adaptive and hypothesis testing clinical trials.

• Summarize the current clinical status of PARP inhibitors and potential biomarker strategies.

• Discuss the challenges impeding the rapid identification and translation of validated biomarkers with acceptable sensitivity and specificity from the laboratory to the clinic.

• Describe strategies for translating research in apoptotic and non-apoptotic death pathways into personalized therapeutic approaches for inducing cell death in the clinic.

2011 McClay Foundation Lecture

• Summarize the major findings from the N9741 clinical trial and describe methods for extracting maximum utility from subsequent prospective large scale clinical studies.

SESSION 4: ACADEMIC AND INDUSTRIAL PARTNERSHIPS IN STRATIFIED MEDICINE

• Discuss the evolution of cancer chemotherapy from its beginnings with drugs targeting DNA or inhibiting synthesis of DNA to the current era of predictive medicine.

• Describe the steps in development from a predictive biomarker to a companion diagnostic able to stratify patients in clinical practice.

PROSTATE CANCER: PROGRESS AND PROMISE

• Interpret new trial data, safety and efficacy for novel investigational therapies

• Consider likely directions for future use of new therapies in combination, and in earlier stage of prostate cancer

• Consider current standards of care for patients with prostate cancer and apply information from this activity to clinical practice
The Centre for Cancer Research & Cell Biology and the Society for Translational Oncology are grateful to the ABPI Northern Ireland Oncology Subgroup, comprising the companies listed below, for kindly agreeing to give financial assistance to support the costs of hosting this event.

The ABPI Northern Ireland Oncology Subgroup comprises the following companies operating for the benefit of patients in Northern Ireland who have contributed to this event:

Amgen Ltd, AstraZeneca plc, Bristol-Myers Squibb Pharmaceuticals Ltd, Celgene, Chugai Pharma UK Limited, Janssen-Cilag Ltd, Merck-Serono Ltd, Novartis Pharmaceuticals UK Ltd, Pfizer Ltd.
The Centre for Cancer Research & Cell Biology and the Society for Translational Oncology gratefully acknowledge the following meeting exhibitors for their sponsorship:

This meeting and subsequent educational materials are supported in part by educational grants from Abbott and Janssen.

Prostate Cancer: Progress and Promise is supported by educational grants from Bayer, Dendreon, Endo Pharmaceuticals and Janssen.
“...The meeting was beyond informative. It was inspiring.”
--John Heneghan, PhD, Post-Doctoral Fellow, Beth Israel Deaconess Medical Center
2010 Meeting Attendee

2011 Chabner Colloquium
Collaboration in Cancer Drug Trials

Featuring a thoughtful look at the potential for collaboration between academia and industry.

This meeting will again focus on topics that bring cancer biology to clinical application: new targets and targeted agents, strategies for profiling and selection of patients for targeted drug trials, and biomarkers and animal models to guide clinical development.

October 24-25, 2011

Norton’s Woods Conference Center
136 Irving Street, Cambridge, Massachusetts

Hosted by
MASSACHUSETTS GENERAL HOSPITAL
CANCER CENTER